Novo Nordisk's 15 milligram (mg)/1.5 milliliter (mL) Norditropin Flexpro pen injector has been only intermittently ... although the FDA's site lists all four presentations as in shortage. Eli Lilly's ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Some investors could be tempted to sell. I think that's a temptation to avoid. Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update are overblown It's not ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the ...

It's the same story with stocks. We saw that happen with Eli Lilly (NYSE: LLY) this week. Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big ...